Xian-Janssen Promotes Its Paliperidone By Means Of Academic Promotion
This article was originally published in PharmAsia News
Executive SummaryThe Chinese Society of Psychiatry, under the Chinese Medical Association, and Xian-Janssen have jointly started a personal and social performance scale training (PSP) course in Guangzhou. The nationwide training program aims to apply scientific psychiatric diagnosis and treatment concepts to clinical practice. Industry observers believe that besides popularizing these concepts, Xian-Janssen is more interested in promoting its schizophrenia drugs. In February this year, the firm introduced in China its extended-release paliperidone tablets, the first FDA-approved anti-psychotic drug that can significantly improve a patient's personal and social functioning, as proven by PSP. Analysts note that pharmaceutical MNCs' advantages in the psychiatry field can be ascribed to their developed academic promotion system. (Click here for more - Chinese Language)
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.